From the Department of Neuroscience, Faculty of Medicine (V.S., J.H., D.W., A.D., S.S., L.V.) Geneva Neuroscience Center (V.S., J.H., D.W., A.D., S.S., L.V.) Swiss Center for Affective Sciences (V.S., J.H., D.W., S.S.), University of Geneva, Geneva, Switzerland Department of Mental Health and Psychiatry, Service of Psychiatric Specialties (S.V., G.M., V.B., A.D., J.-M.A., M.K.) Department of Anesthesiology, Pharmacology, and Intensive Care (L.V.), University Hospitals of Geneva, Geneva, Switzerland Faculty of Medicine, University of Namur, Namur, Belgium (M.D.).
Anesthesiology. 2019 Jun;130(6):923-935. doi: 10.1097/ALN.0000000000002667.
The antidepressant effect of ketamine is associated with increased activity in the reward circuitry of the brain and a suppression of circuitry that mediates perceptual processing of negative emotions. The duration of ketamine effect on these brain structures remains to be defined.
As expected, ketamine administration led to an improvement in mood and global vigilance. The improvement in mood was accompanied by an increased recruitment of the orbitofrontal cortex, ventral striatum, medial substantial nigra and ventral tegmental area, structures that are part of the reward circuitry.Responses in the mesolimbic structures (amygdala, medial substantial nigra and ventral tegmental area, orbitofrontal cortex) to negative stimuli were decreased after ketamine administration.The data are consistent with the premise that ketamine induces sustained changes in the mesolimbic neural circuits to reset pathological reward and emotional processing.
Ketamine rapidly improves maladaptive mood states in major depressive disorder, and some of the neural substrates underlying this therapeutic effect have been identified. This study aimed to identify functional changes within neural networks that may underlie the impact of ketamine on both reward and emotional processing in patients with treatment-resistant major depression.
Ten adult patients with a Montgomery-Åsberg Depression Rating Scale score above 25 were enrolled to receive a single intravenous administration of ketamine (0.5 mg/kg). Patients' performance along with related neural network activations were analyzed in a game-like reward task and in an emotional judgment task using functional magnetic resonance imaging 1 day before and 1 and 7 days after ketamine administration.
A significant correlation (R = 0.46, P = 0.03) between the improvement of depression scores and the enhanced reaction time for positive items was found in the game-like reward task 1 day after ketamine administration. This enhanced sensitivity for rewarded items was accompanied by increased activity of reward-related brain regions, including the orbitofrontal cortex, ventral striatum, and the ventral tegmental area, an effect that persisted up to 1 week after ketamine injection. In the emotional judgment task, it was found that ketamine rapidly modified local brain activities in response to emotionally negative, positive, or neutral stimuli in the amygdala, insula, anterior cingulate cortex, and in the ventral tegmental area.
Single bolus ketamine administration rapidly triggers lasting changes in mesolimbic neural networks to improve pathologic reward and emotional processing in patients with major depressive disorder.
氯胺酮的抗抑郁作用与大脑奖励回路的活动增加以及对介导负面情绪感知处理的回路的抑制有关。氯胺酮对这些大脑结构的作用持续时间仍有待确定。
正如预期的那样,氯胺酮给药导致情绪和整体警觉性改善。情绪改善伴随着眶额皮层、腹侧纹状体、内侧黑质和腹侧被盖区的招募增加,这些结构是奖励回路的一部分。氯胺酮给药后,对负性刺激的中边缘结构(杏仁核、内侧黑质和腹侧被盖区、眶额皮层)的反应减少。这些数据与氯胺酮诱导中边缘神经回路持续变化以重置病理性奖励和情绪处理的前提一致。
氯胺酮可迅速改善重度抑郁症患者的适应不良情绪状态,并且已经确定了这种治疗效果的一些神经基础。本研究旨在确定可能构成氯胺酮对治疗抵抗性重度抑郁症患者的奖励和情绪处理影响的神经网络内的功能变化。
招募了 10 名蒙哥马利-Åsberg 抑郁评定量表评分高于 25 的成年患者接受单次静脉注射氯胺酮(0.5mg/kg)。在氯胺酮给药前 1 天、1 天和 7 天,使用功能磁共振成像分析患者的表现以及相关的神经网络激活情况,在类似游戏的奖励任务和情绪判断任务中进行。
在氯胺酮给药后 1 天的类似游戏的奖励任务中,发现抑郁评分的改善与积极项目的反应时间增强之间存在显著相关性(R=0.46,P=0.03)。这种对奖励项目的敏感性增强伴随着奖励相关大脑区域的活动增加,包括眶额皮层、腹侧纹状体和腹侧被盖区,这种效应持续到氯胺酮注射后 1 周。在情绪判断任务中,发现氯胺酮迅速改变了杏仁核、岛叶、前扣带回皮质和腹侧被盖区对情绪负性、正性或中性刺激的局部脑活动。
单次推注氯胺酮可迅速引发中边缘神经网络的持久变化,改善重度抑郁症患者的病理性奖励和情绪处理。